Topics:

Who's News

Who's News

 

AROUND TOWN
 
The AACR has elected Judy E. Garber, MD, MPH (left), as president-elect. Dr. Garber is the director of the cancer risk and prevention program at the Dana-Farber Cancer Institute in Boston and an associate professor of medicine at Harvard Medical School. She is also an associate physician of medicine and attending physician of medical service at Brigham and Women’s Hospital. In other AACR news, William N. Hait, MD, PhD, has been appointed treasurer. Dr. Hait is senior vice president and worldwide therapeutic area head of oncology of Johnson & Johnson Pharmaceuticals Research & Development. Finally, the following physicians were named to the AACR board of directors for the 2010-2013 term: Todd R. Golub, MD, Jennifer Rubin Grandis, MD, Kornelia Polyak, MD, PhD, and Owen W. Witte, MD.
 
Al B. Benson III, MD, is the new president of the Association of Community Cancer Centers (ACCC). Dr. Benson is a professor of medicine in the division of hematology/oncology at the Feinberg School of Medicine and associate director for clinical investigations at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University in Chicago.
 
INTERNATIONAL
 
Miguel Villalona-Calero, MD (left), has been named director of the newly formed division of medical oncology at the Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute in Columbus. Dr. Villalona-Calero is a native of the Dominican Republic. He directs Ohio State’s solid tumors experimental therapeutics program and is a member of the NCI investigational drug steering committee. The medical oncology unit was previously part of the department of internal medicine’s division of hematology and medical oncology.
 
 

Sir David P. Lane, PhD, has been elected to serve on the AACR board of directors. Sir David is the chief scientist at the Agency for Science, Technology and Research (A*STAR), Singapore and chief scientist at Cancer Research UK in London. His research focuses on using the p53 system to develop new treatments for cancer.

 
Loading comments...
Please Wait 20 seconds or click here to close